Drug-Resistant Epilepsy Treatment
Feb 09, 2026
Drug-Resistant Epilepsy: Evolving Treatment Strategies for a High‑Unmet‑Need Population
Summary Drug-resistant epilepsy affects 20-40% of epilepsy patients in the US, rising to 30-40% in adults versus 7-20% in children, with similar rates (over 25%) in Europe; about one-quarter of newly diagnosed cases progress to DRE. Vagus Nerve Stimulation (VNS Therapy by LivaNova) is FDA-approved for drug-r...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
